Human medicines European public assessment report (EPAR): Etcamah, camizestrant, Date of authorisation: 20/07/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Abrysvo, respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Vfend, voriconazole, Date of authorisation: 19/03/2002, Revision: 59, Status: Authorised

Human medicines European public assessment report (EPAR): Tolucombi, telmisartan,hydrochlorothiazide, Date of authorisation: 13/03/2013, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Fluenz, influenza vaccine (live attenuated, nasal), Date of authorisation: 03/06/2024, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Date of authorisation: 18/01/2021, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Retacrit, epoetin zeta, Date of authorisation: 18/12/2007, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Tafamidis Accord, tafamidis, Status: Opinion

Human medicines European public assessment report (EPAR): Ruxolitinib Viatris, ruxolitinib hemifumarate, Status: Opinion

Human medicines European public assessment report (EPAR): Ogsiveo, nirogacestat, Date of authorisation: 14/08/2025, Revision: 3, Status: Authorised